JASMA

Hepatocellular carcinoma, often shortened to HCC, is the most common type of primary liver cancer. It does not usually arrive with a marching band, dramatic symptoms, or a polite calendar invite. In many people, it develops quietly in the background of chronic liver disease, especially cirrhosis. That is exactly why screening and surveillance for hepatocellular carcinoma matter so much.

The goal is simple: find liver cancer early, when treatment options are stronger and outcomes may be better. The process is not about testing everyone walking down the street. Instead, HCC surveillance focuses on people who have a higher risk because of conditions such as cirrhosis, chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, or certain inherited liver disorders.

Think of HCC surveillance as a smoke detector for the liver. It does not prevent every fire, and it cannot tell you everything about the house. But when used regularly in the right building, it can make an enormous difference.

What is hepatocellular carcinoma?

Hepatocellular carcinoma is cancer that begins in hepatocytes, the main working cells of the liver. These cells are busy little overachievers. They process nutrients, filter toxins, help with digestion, support blood clotting, and manage many chemical tasks that keep the body running smoothly. When long-term inflammation and scarring damage the liver, some hepatocytes may develop genetic changes that allow cancer to grow.

Most cases of HCC occur in people with cirrhosis, which is advanced scarring of the liver. Cirrhosis can result from many causes, including hepatitis B virus, hepatitis C virus, heavy alcohol use, metabolic liver disease related to obesity and diabetes, autoimmune liver disease, and inherited conditions such as hemochromatosis.

One important exception is hepatitis B. Unlike many other liver diseases, chronic hepatitis B can increase the risk of hepatocellular carcinoma even before cirrhosis develops. That makes risk-based surveillance especially important for some people with hepatitis B infection.

Screening vs. surveillance: what is the difference?

The terms “screening” and “surveillance” are often used together, and sometimes people use them as if they mean the same thing. They are related, but there is a useful distinction.

Screening

Screening usually means testing people who do not have symptoms to look for early signs of disease. For example, colonoscopy screens for colorectal cancer, and mammography screens for breast cancer.

Surveillance

Surveillance means repeated screening over time in people known to be at higher risk. In hepatocellular carcinoma, surveillance is the more accurate term because most people being monitored already have a defined risk factor, such as cirrhosis or chronic hepatitis B.

In plain English: one test is a snapshot. Surveillance is the photo album.

Who should be considered for HCC surveillance?

HCC surveillance is not recommended for every adult. It is mainly for people whose risk is high enough that regular testing is likely to help more than it harms. The exact recommendation can vary depending on the guideline, liver disease cause, age, ethnicity, family history, and overall health. Still, several major risk groups are commonly recognized.

People with cirrhosis

Adults with cirrhosis from almost any cause are typically considered candidates for hepatocellular carcinoma surveillance. This includes cirrhosis caused by hepatitis C, hepatitis B, alcohol-associated liver disease, metabolic dysfunction-associated steatohepatitis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and hereditary hemochromatosis.

The reason is straightforward: cirrhosis is the strongest and most consistent risk factor for HCC. Even if the original liver disease is treated, scarring may remain, and cancer risk may not disappear completely.

People with chronic hepatitis B

Chronic hepatitis B deserves special attention because HCC can occur even without cirrhosis. Surveillance may be recommended for people with hepatitis B who have cirrhosis, a family history of liver cancer, hepatitis delta coinfection, HIV coinfection, or demographic risk factors such as age, sex, and region of origin.

For example, clinicians often consider surveillance for men over 40 from regions where hepatitis B is common, women over 50 from those regions, some people of African ancestry at younger ages, and anyone with chronic hepatitis B plus a first-degree family history of HCC. The best plan should be individualized by a liver specialist or knowledgeable clinician.

People with hepatitis C after cure

Modern hepatitis C treatment can cure the infection in most patients, which is a medical win worth celebrating with confetti, or at least a very enthusiastic cup of coffee. However, people who already had cirrhosis before hepatitis C cure generally still need HCC surveillance. The risk drops, but it does not become zero.

People with MASLD or MASH

Metabolic dysfunction-associated steatotic liver disease, formerly commonly discussed under the umbrella of fatty liver disease, is increasingly linked to cirrhosis and liver cancer. People with MASLD or MASH who have cirrhosis should be considered for HCC surveillance. People without advanced fibrosis are not usually screened routinely, although research is evolving because some HCC cases can occur without cirrhosis.

What tests are used for hepatocellular carcinoma surveillance?

The most common surveillance strategy is liver ultrasound with a blood test called alpha-fetoprotein, or AFP, about every six months. This combination is widely used because it is reasonably accessible, noninvasive, and practical for repeated monitoring.

Liver ultrasound

Ultrasound uses sound waves to create images of the liver. It does not involve radiation, does not usually require contrast dye, and is often less expensive than CT or MRI. During the exam, a technologist moves a probe across the abdomen while looking for suspicious liver nodules.

However, ultrasound is not perfect. Its quality can be affected by body habitus, obesity, severe liver nodularity, intestinal gas, and operator experience. In patients with MASLD-related cirrhosis, ultrasound can sometimes provide a limited view. When the view is poor, clinicians may consider alternative imaging such as MRI or CT for surveillance in selected cases.

Alpha-fetoprotein blood test

AFP is a protein that can be elevated in some people with hepatocellular carcinoma. It can also rise for reasons that are not cancer, including active liver inflammation, pregnancy, and other conditions. On the flip side, some people with early HCC have normal AFP levels. AFP is useful, but it is not a magical liver crystal ball.

That is why AFP should not be the only surveillance tool when ultrasound is available and adequate. Used with ultrasound, AFP may improve detection, especially when tumors are small or difficult to see.

CT and MRI

Multiphasic CT and contrast-enhanced MRI are usually used for diagnostic evaluation after an abnormal surveillance result, such as a liver nodule or concerning AFP trend. They are more detailed than ultrasound and can show the blood-flow pattern of liver tumors.

Routine CT for every surveillance round is not generally preferred because of radiation exposure and cost. MRI avoids radiation but is more expensive, less available in some areas, and may require contrast. Abbreviated MRI is an emerging approach that may become more common, especially for people whose ultrasound exams are repeatedly limited.

How often should HCC surveillance be done?

For most people who qualify, hepatocellular carcinoma surveillance is performed every six months. This interval balances tumor biology, test performance, patient convenience, and cost. Testing once a year may miss tumors while they are still small. Testing every month would turn life into a waiting room and has not been shown to provide enough added benefit for routine care.

The six-month schedule is easy to understand but surprisingly easy to miss. A patient may feel well, a clinic may forget to order the next exam, insurance may cause delays, or life may simply happen. Unfortunately, HCC does not pause politely because someone had a busy week.

What happens if surveillance finds something abnormal?

An abnormal result does not automatically mean cancer. Small nodules are common in cirrhosis, and AFP can rise for noncancerous reasons. Still, abnormal findings should be taken seriously and followed with a clear plan.

If ultrasound shows a small nodule

Very small nodules, especially those under 1 centimeter, may be monitored with repeat ultrasound and AFP at a shorter interval. Many tiny nodules are not cancer, and immediate invasive testing may create unnecessary anxiety and procedures.

If ultrasound shows a nodule 1 centimeter or larger

A nodule that is 1 centimeter or larger usually requires diagnostic imaging with multiphasic CT or MRI. These tests look for classic HCC imaging features, including arterial phase enhancement and washout on later phases. In many patients with cirrhosis, imaging can diagnose HCC without a biopsy.

If AFP is rising

A rising AFP level, especially when it is clearly abnormal or increasing over time, may also trigger CT or MRI even if the ultrasound does not show a mass. Trends matter. A single number is helpful, but the pattern over time can be more informative.

Why early detection changes the treatment conversation

When HCC is found early, patients may have options such as surgical resection, liver transplantation, or local ablation. These treatments can sometimes be curative. When cancer is found later, treatment may still help, but the focus often shifts toward controlling disease rather than eliminating it.

Early-stage HCC can be sneaky because people may feel completely fine. Waiting for symptoms is a risky strategy. By the time symptoms such as weight loss, abdominal swelling, jaundice, worsening fatigue, or pain appear, the cancer may already be advanced. In liver cancer, “I feel fine” is comforting, but it is not a surveillance plan.

Common barriers to effective HCC surveillance

One of the biggest problems in HCC surveillance is not the lack of guidelines. It is getting surveillance done consistently. Real-world adherence is often lower than it should be.

Patients may not know they are at risk

Some people with cirrhosis do not realize they have cirrhosis. Others had hepatitis C treated years ago and assume their liver cancer risk vanished completely. Some people with hepatitis B feel healthy for decades and may not know they need monitoring.

Clinics may not have reminder systems

Surveillance works best when healthcare teams use registries, automatic reminders, standing orders, and follow-up tracking. Without a system, the six-month schedule can quietly stretch to nine months, then twelve, then “Wait, when was my last ultrasound?”

Access can be difficult

Transportation, cost, insurance approval, language barriers, rural distance, and limited appointment availability can all interfere with screening. A perfect guideline does not help if the patient cannot get to the imaging center.

Ultrasound quality may be limited

If the ultrasound report repeatedly says visualization is limited, clinicians should not simply shrug and continue as usual forever. The surveillance strategy may need adjustment, especially in patients with obesity or very nodular livers.

How patients can make surveillance easier

Patients do not have to become liver experts, but a few habits can make a real difference.

• Ask whether you qualify. If you have cirrhosis, chronic hepatitis B, or advanced liver fibrosis, ask your clinician directly about HCC surveillance.
• Schedule the next test early. Before leaving the clinic, ask when the next ultrasound and AFP test should happen.
• Track dates. A phone reminder labeled “liver ultrasound” is not glamorous, but it is useful.
• Keep copies of results. Knowing whether a nodule was seen, whether AFP changed, and whether ultrasound quality was adequate helps with follow-up.
• Do not ignore abnormal results. If CT or MRI is recommended, schedule it promptly.
• Manage the underlying liver disease. Treat hepatitis, avoid alcohol when advised, manage diabetes, maintain a healthy weight, and follow liver specialist recommendations.

Prevention still matters

Surveillance looks for cancer early, but prevention lowers the chance of cancer developing in the first place. Hepatitis B vaccination is one of the most powerful liver cancer prevention tools available. Testing for hepatitis B and C is also important because many people do not know they are infected.

For people with hepatitis B, antiviral therapy can reduce the risk of liver cancer by suppressing viral activity. For people with hepatitis C, curative antiviral treatment can greatly lower risk, especially when started before cirrhosis develops. For people with metabolic liver disease, managing weight, blood sugar, cholesterol, and blood pressure can help protect the liver. For people with alcohol-associated liver disease, stopping alcohol use can be lifesaving.

The best liver cancer strategy is not one move. It is a team sport: prevention, treatment of liver disease, regular surveillance, timely follow-up, and access to expert care.

Special considerations for clinicians and care teams

For healthcare systems, effective HCC surveillance requires more than telling patients to “come back in six months.” A strong program identifies eligible patients, orders ultrasound and AFP on schedule, tracks completion, reviews results, and ensures abnormal findings receive diagnostic follow-up.

Electronic health record reminders can help. So can patient navigation, multilingual education, bundled lab-and-imaging appointments, and direct scheduling before the patient leaves the clinic. In high-risk populations, outreach is not a luxury. It is part of quality care.

Care teams should also document ultrasound visualization quality. If the liver is not well seen, the result may create false reassurance. For patients with repeatedly inadequate ultrasound exams, MRI- or CT-based surveillance may be appropriate after considering risks, benefits, availability, and patient factors.

Experience-based insights: what HCC surveillance feels like in real life

On paper, screening and surveillance for hepatocellular carcinoma looks tidy: ultrasound plus AFP every six months, follow abnormal findings, repeat forever if risk remains. In real life, it feels more human, more messy, and sometimes more emotional.

Many patients hear “liver cancer surveillance” and immediately imagine the worst. The word cancer has a way of walking into a room wearing heavy boots. A helpful clinician explains that surveillance does not mean cancer is present. It means the patient has a risk factor, and the team is watching carefully so that if a problem appears, it is caught early. That single explanation can lower fear dramatically.

Another common experience is “surveillance fatigue.” A person may go for ultrasound after ultrasound, year after year, and every result is normal. That is good news, of course, but it can also make the next appointment feel optional. Patients may think, “Nothing has happened so far, so maybe I can skip this one.” This is where education matters. Surveillance only works when it is repeated consistently. The quiet months are not wasted months; they are the point.

Some patients also feel frustrated when an ultrasound finds a tiny nodule that later turns out to be harmless. The waiting period before repeat imaging or MRI can be stressful. It helps to explain that cirrhotic livers often develop benign nodules and that careful follow-up is how clinicians separate harmless findings from dangerous ones. Not every alarm means a fire, but every alarm deserves attention.

People with cured hepatitis C often need extra counseling. They may feel proud and relieved after treatment, as they should. But if cirrhosis is already present, the liver still carries a cancer risk. A good analogy is repairing a roof after years of storm damage. Fixing the leak matters, but the old damage still needs inspection.

For patients with obesity or MASLD-related cirrhosis, ultrasound can sometimes be technically limited. This can feel discouraging, especially when the patient did everything asked. The message should not be blame. The message should be adjustment: if ultrasound cannot see well enough, the care plan may need a better imaging tool.

The most successful surveillance experiences tend to share three features. First, the patient knows why testing is needed. Second, the clinic has a reliable reminder system. Third, abnormal results trigger fast, organized follow-up. When those pieces are in place, surveillance becomes less like a confusing medical chore and more like a routine safety check.

In the end, HCC surveillance is an act of patience. It is not flashy. It does not usually produce dramatic news. But for the right patient, done at the right interval, with the right follow-up, it can shift the story from “found too late” to “found early enough to treat.” That is a quiet victory, but in liver cancer care, quiet victories count.

Conclusion

Screening and surveillance for hepatocellular carcinoma are essential parts of caring for people at high risk of liver cancer. The main goal is early detection, especially in patients with cirrhosis or chronic hepatitis B. For most eligible patients, surveillance involves liver ultrasound and AFP testing every six months.

The process is not perfect. Ultrasound can miss early tumors, AFP can be misleading, and follow-up systems can fail. But when surveillance is done consistently and abnormal results are evaluated promptly, it can improve the chances of finding HCC at a stage when curative treatment may still be possible.

For patients, the most important questions are simple: “Am I at risk?” “Do I need surveillance?” and “When is my next test?” For clinicians, the challenge is building systems that make the right thing easy to do every six months. The liver may be quiet, but good surveillance helps make sure it is not ignored.